GlassScriptPhysician profile
Andrew Sorial
NPI 1255725602
$8,969.54
in general payments reported to CMS, 2019-2025
24 companies · $58.86 in 2025
The $58.86 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $991 · 2020: $1,234 · 2021: $2,652 · 2022: $3,294 · 2023: $426 · 2024: $313 · 2025: $58.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,410.00 | 2021-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,017.87 | 2019-2023 | Abilify Mycite, Rexulti |
| Teva Pharmaceuticals USA, INC. | $826.26 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $822.10 | 2020-2023 | Trintellix |
| Allergan, INC. | $788.80 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $653.93 | 2020-2023 | |
| Lundbeck LLC | $470.41 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $437.49 | 2022-2024 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $418.49 | 2020-2022 | |
| Alkermes, INC. | $367.74 | 2019-2023 | Lybalvi |
| Corium, LLC | $290.79 | 2022-2023 | Azstarys |
| Neurocrine Biosciences, INC. | $222.55 | 2019-2023 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $182.07 | 2020-2021 | |
| Almatica Pharma LLC | $178.19 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $171.60 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $145.39 | 2020-2022 | |
| Bausch Health US, LLC | $144.52 | 2020-2023 | Aplenzin, Wellbutrin |
| Alfasigma USA, INC. | $141.77 | 2020-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $82.80 | 2019 | |
| Merck Sharp & Dohme LLC | $59.10 | 2021-2023 | Belsomra |
| Axsome Therapeutics, INC. | $58.86 | 2025 | Auvelity |
| Jazz Pharmaceuticals INC. | $43.69 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $21.97 | 2024 | Cobenfy |
| Eisai INC. | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Sorial listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.